TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

AMELUZ

AMINOLEVULINIC ACID HYDROCHLORIDE
Approved 2016-05-10
2
Indications
--
Phase 3 Trials
9
Years on Market

Details

Status
Prescription
First Approved
2016-05-10
Routes
TOPICAL
Dosage Forms
GEL

Companies

AMELUZ Approval History

Loading approval history...

What AMELUZ Treats

1 indications

AMELUZ is approved for 1 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Actinic Keratosis
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AMELUZ FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

AMELUZ, in combination with photodynamic therapy (PDT) using BF-RhodoLED ® or RhodoLED ® XL lamp, a narrowband, red light illumination source, is indicated for lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp. AMELUZ, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED or RhodoLED XL lamp, is indicated for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp .

AMELUZ Patents & Exclusivity

Latest Patent: Dec 2043
Exclusivity: Oct 2027

Patents (3 active)

US12280146 Expires Dec 8, 2043
US11235169 Expires Oct 15, 2040
US11540981 Expires Feb 7, 2028

Exclusivity

D-194 Until Oct 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.